Fast, low-cost breast biopsy imaging for use in Ghana

Breast core-needle diagnostics in LMICs via millifluidics and direct-to-digital imaging: development and validation in Ghana

NIH-funded research University of California at Davis · NIH-11162315

This project is building a compact system that turns breast needle biopsies into diagnostic-quality digital images and quick lab tests to help people in Ghana and similar low-resource places get faster breast cancer diagnosis and staging.

Quick facts

Grant typeU01 cooperative agreement
Study typeNIH-funded research
Funding institutionUniversity of California at Davis NIH-funded
Lab location1 site (Davis, United States)
Project IDNIH-11162315 on NIH RePORTER

What this research studies

From my perspective as a patient, the team is creating an automated instrument that handles needle biopsy tissue without manual slide preparation using a millifluidic cartridge. It then captures high-resolution, slide-free digital images and adds rapid immunofluorescence tests that can guide treatment decisions near the time of biopsy. The project will also develop AI tools to help triage cases or support local diagnosis when a pathologist is not immediately available. The system will be developed and clinically validated using samples and workflows in Ghana to see if it can produce reliable, faster results at lower cost.

Who could benefit from this research

Good fit: People undergoing core-needle breast biopsy for suspected breast cancer at participating clinical sites (particularly in Ghana) are the ideal candidates for this work.

Not a fit: People who do not need a breast biopsy, who already have a confirmed diagnosis and treatment plan, or who are outside participating locations are unlikely to benefit directly from this project.

Why it matters

Potential benefit: If successful, this could shorten the time to accurate breast cancer diagnosis and staging, lower costs, and help patients in low-resource settings begin appropriate treatment sooner.

How similar studies have performed: Digital pathology and AI tools have shown promise in other settings, but combining millifluidic, slide-free imaging with rapid immunofluorescence for point-of-care breast biopsy diagnosis in low-resource countries is largely novel and is now being validated.

Where this research is happening

Davis, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Breast CancerCancer StagingCancers
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.